For research use only. Not for therapeutic Use.
Remogliflozin etabonate (Cat.No:I009005), also known as GSK 189075A or GSK 189075, is a SGLT2 inhibitor under development for the treatment of type 2 diabetes. Remogliflozin etabonate is a pro-drug of remogliflozin. Remogliflozin inhibits the sodium-glucose transport proteins (SGLT), which are responsible for glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine. Remogliflozin is selective for SGLT2.
| Catalog Number | I009005 |
| CAS Number | 442201-24-3 |
| Synonyms | GSK189075A; GSK-189075A; GSK 189075A; GSK189075; GSK-189075; GSK 189075; Remogliflozin etabonate.;ethyl (((2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-((4-(4-isopropoxybenzyl)-1-isopropyl-5-methyl-1H-pyrazol-3-yl)oxy)tetrahydro-2H-pyran-2-yl)methyl) carbonate |
| Molecular Formula | C26H38N2O9 |
| Purity | ≥95% |
| Target | SGLT |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| Reference | </br>1:Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice. Nakano S, Katsuno K, Isaji M, Nagasawa T, Buehrer B, Walker S, Wilkison WO, Cheatham B.J Clin Exp Hepatol. 2015 Sep;5(3):190-8. doi: 10.1016/j.jceh.2015.02.005. Epub 2015 Apr 28. PMID: 26628836 Free PMC Article</br>2:Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus. Mikhail N.Expert Opin Investig Drugs. 2015;24(10):1381-7. doi: 10.1517/13543784.2015.1061501. Epub 2015 Aug 14. Review. PMID: 26288025 </br>3:Remogliflozin etabonate : a novel SGLT2 inhibitor for treatment of diabetes mellitus. Mikhail N.Expert Opin Investig Drugs. 2015 Aug 14:1-7. [Epub ahead of print] PMID: 26271274 </br>4:Pharmacokinetics and Pharmacodynamics of the SGLT2 Inhibitor Remogliflozin Etabonate in Subjects with Mild and Moderate Renal Impairment. O/’Connor-Semmes R, Walker S, Kapur A, Hussey EK, Ye J, Wang-Smith L, Tao W, Dobbins RL, Cheatham B, Wilkison WO.Drug Metab Dispos. 2015 Jul;43(7):1077-83. doi: 10.1124/dmd.114.062828. Epub 2015 May 1. PMID: 25934577 Free Article</br>5:Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes. Sykes AP, Kemp GL, Dobbins R, O/’Connor-Semmes R, Almond SR, Wilkison WO, Walker S, Kler L.Diabetes Obes Metab. 2015 Jan;17(1):98-101. doi: 10.1111/dom.12393. Epub 2014 Nov 3. PMID: 25238025 </br>6:Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes. Sykes AP, O/’Connor-Semmes R, Dobbins R, Dorey DJ, Lorimer JD, Walker S, Wilkison WO, Kler L.Diabetes Obes Metab. 2015 Jan;17(1):94-7. doi: 10.1111/dom.12391. Epub 2014 Nov 3. PMID: 25223369 </br>7:First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus. Kapur A, O/’Connor-Semmes R, Hussey EK, Dobbins RL, Tao W, Hompesch M, Smith GA, Polli JW, James CD Jr, Mikoshiba I, Nunez DJ.BMC Pharmacol Toxicol. 2013 May 13;14:26. doi: 10.1186/2050-6511-14-26. PMID: 23668634 Free PMC Article</br>8:Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. Hussey EK, Kapur A, O/’Connor-Semmes R, Tao W, Rafferty B, Polli JW, James CD Jr, Dobbins RL.BMC Pharmacol Toxicol. 2013 Apr 30;14:25. doi: 10.1186/2050-6511-14-25. PMID: 23631443 Free PMC Article</br>9:Regional gastrointestinal delivery of remogliflozin etabonate in humans. O/’Connor-Semmes RL, Sandefer EP, Hussey EK, Tao W, Doll WJ, Page RC, Dobbins R.Biopharm Drug Dispos. 2013 Mar;34(2):79-86. doi: 10.1002/bdd.1824. Epub 2013 Jan 7. PMID: 23111980 </br>10:Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes. Mudaliar S, Armstrong DA, Mavian AA, O/’Connor-Semmes R, Mydlow PK, Ye J, Hussey EK, Nunez DJ, Henry RR, Dobbins RL.Diabetes Care. 2012 Nov;35(11):2198-200. doi: 10.2337/dc12-0508. Epub 2012 Sep 25. PMID: 23011728 Free PMC Article |
